Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CorMedix Inc. (CRMD)

CorMedix Q2 revenue rises to $101.9M; raises adjusted EBITDA guidance

Positive Impact 4 of 5 earnings Written later

CorMedix reported second-quarter 2026 revenue of $101.9 million, up from $39.7 million a year earlier, and net income of $26.0 million, up from $19.8 million. The company kept its full-year 2026 revenue guidance of $325 million to $345 million and raised its adjusted EBITDA guidance to $125 million to $140 million, which matters to shareholders because it signals stronger expected profitability.

Key points

  • Q2 2026 revenue of $101.9 million: $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio
  • Q2 2026 net income of $26.0 million, or $0.33 basic and $0.29 diluted per share, versus $19.8 million in Q2 2025
  • Adjusted EBITDA of $58.7 million in Q2 2026 versus $22.4 million a year earlier; full-year adjusted EBITDA guidance raised to $125 million to $140 million
  • Full-year 2026 revenue guidance maintained at $325 million to $345 million; cash and short-term investments of $256.7 million at June 30, 2026

The filing

CompanyCorMedix Inc. (CRMD)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:32 AM ET
Accession number0001410098-26-000054

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.